A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment

NCT01232296 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

162

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: dovitinib
DRUG: sorafenib

Sponsor

Novartis Pharmaceuticals